<p>In Molecular Medicine a wide range of methods are applied to analyze the genome to find genetic predictors of human disease. Apart from predisposing disease, genetic variations may also serve as genetic markers in the search for factors underlying complex diseases. Additionally, they provide a means to distinguish between species, analyze evolutionary relationships and subdivide species into strains. </p><p>The development and improvement of laboratory techniques and computational methods was a spin-off effect of the Human Genome Project. The same techniques for analyzing genomic sequence variations may be used independent of organism or source of DNA or RNA. In this thesis, methods for high-throughput analysis of sequence variations were developed, evaluated and applied. </p><p>The performance of several genotyping assays were investigated prior to genotyping 4000 samples in a co-operative genetic epidemiological study. Sequence variations in the estrogen receptor alpha gene were found to be associated with an increased risk of breast and endometrial cancer in Swedish women.</p><p>Whole genome amplification (WGA) enables large scale genetic analysis of sparse amounts of biobanked DNA samples. The performance of two WGA methods was evaluated using four-color minisequencing on tag-arrays. Our in-house developed assay and “array of arrays” format allow up to 80 samples to be analyzed in parallel on a single microscope slide. Multiple displacement amplification by the Φ29 DNA polymerase gave essentially identical genotyping results as genomic DNA. To facilitate accurate method comparisons, a cluster quality assessment approach was established and applied to assess the performance of four commercially available DNA polymerases in the tag-array minisequencing assay. </p><p>A microarray method for genotyping human group A rotavirus (HRV) was developed and applied to an epidemiological survey of infectious HRV strains in Nicaragua. The method combines specific capture of amplified viral sequences on microarrays with genotype-specific DNA-polymerase mediated extension of capture oligonucleotides with fluorescent dNTPs.</p>

<p>2-Methoxyestradiol (2-ME), a metabolite of 17β-estradiol, is a potent antitumor and antiangiogenesis agent in vitro and in vivo. This study aimed to investigate the effects of 2-ME on human cervical and endometrial cancers in vitro and in vivo. Human cervical cancer HeLaS3 cells, endometrial cancer HEC-1-A and RL-95-2 cells, and severe combined immune deficient (SCID) mice were used. On cervical cancer HeLaS3 cells, 2-ME inhibited the cell growth which is accompanied by apoptosis via iNOS pathway and by G₂/M cell cycle arrest. 2-ME had slight effects on normal cervical epithelial cells. In vivo on SCID mice, 2-ME (75 mg/kg p.o.) inhibited the growth of human cervical carcinoma by 34% (p < 0.05) and showed slight side effects to liver and spleen. On human endometrial cancer cells (HEC-1-A and RL-95-2 cells), 2-ME inhibited the growth by blocking cell cycle progress in S- and G₂/M-phase in both cell types, and by inducing apoptosis in HEC-1-A cells and by causing necrosis in RL-95-2 cells. 2-ME had no effects on normal endometrial cells. The apoptotic effect, in HEC-1-A cells, was prevented by iNOS-inhibitor 1400W and eliminated by Caspase-inhibitor Z-VAD-FMK. The necrosis, on RL-95-2 cells, was due to a severe disruption of the mitochondrial membrane potential. Unfortunately, 2-ME had no significant effects on endometrial cancer xenografts. It showed slight toxicity to liver, spleen and proliferative effect on uterus. In conclusion, 2-ME inhibits the growth of human cervical and endometrial cancer cells in vitro. However, a weaker anti-tumor effect was observed in our animal model and 2-ME was slightly toxic to liver and spleen. Considering the proliferative effect on uterus, 2-ME might not be a suitable therapeutic agent in gynecological tumors.</p>

In Molecular Medicine a wide range of methods are applied to analyze the genome to find genetic predictors of human disease. Apart from predisposing disease, genetic variations may also serve as genetic markers in the search for factors underlying complex diseases. Additionally, they provide a means to distinguish between species, analyze evolutionary relationships and subdivide species into strains. The development and improvement of laboratory techniques and computational methods was a spin-off effect of the Human Genome Project. The same techniques for analyzing genomic sequence variations may be used independent of organism or source of DNA or RNA. In this thesis, methods for high-throughput analysis of sequence variations were developed, evaluated and applied. The performance of several genotyping assays were investigated prior to genotyping 4000 samples in a co-operative genetic epidemiological study. Sequence variations in the estrogen receptor alpha gene were found to be associated with an increased risk of breast and endometrial cancer in Swedish women. Whole genome amplification (WGA) enables large scale genetic analysis of sparse amounts of biobanked DNA samples. The performance of two WGA methods was evaluated using four-color minisequencing on tag-arrays. Our in-house developed assay and “array of arrays” format allow up to 80 samples to be analyzed in parallel on a single microscope slide. Multiple displacement amplification by the Φ29 DNA polymerase gave essentially identical genotyping results as genomic DNA. To facilitate accurate method comparisons, a cluster quality assessment approach was established and applied to assess the performance of four commercially available DNA polymerases in the tag-array minisequencing assay. A microarray method for genotyping human group A rotavirus (HRV) was developed and applied to an epidemiological survey of infectious HRV strains in Nicaragua. The method combines specific capture of amplified viral sequences on microarrays with genotype-specific DNA-polymerase mediated extension of capture oligonucleotides with fluorescent dNTPs.

Lynch syndrome (Hereditary Nonpolyposis Colorectal Cancer, HNPCC) is the most common hereditary syndrome predisposing to colorectal cancer, accounting for 1-3% of all colorectal cancer. This multi-organ cancer predisposition syndrome is caused by mutations in the mismatch repair (MMR) genes, especially MLH1 and MSH2, and to lesser extents MSH6 and PMS2, which lead to widespread genetic instability and thus microsatellite instability (MSI). Hereditary cancer often manifests in two or more tumours in a single individual; 35-40% of Lynch syndrome patients have synchronous or metachronous tumours of the two major Lynch syndrome-related cancers: colorectal and endometrial. The main purposes of the work underlying this thesis were to identify persons at risk of Lynch syndrome or other types of hereditary colorectal cancer, to estimate the cancer risks associated with these predispositions and to identify the underlying genetic causes. A population-based cohort of 78 persons with double primary colorectal or colorectal and endometrial cancer was identified. Cancer risks in their 649 first-degree relatives were estimated in relation to tumour MSI status (positive or negative) and age at diagnosis (before or after 50 years of age) in the probands. The overall standardised incidence ratio was 1.69 (95% CI; 1.39-2.03). The highest risks for Lynch syndrome-associated cancers: (colorectal, endometrial, ovarian and gastric) were found in families with young MSI-positive probands, likely representing Lynch syndrome families. Importantly, no overall risk was found in families with old probands, irrespective of MSI status. Blood samples were available from 24 MSI-positive patients for mutation screening of MLH1, MSH2 and MSH6. Sequence variants or rearrangements predicted to affect protein function were found in 16 patients. Six novel variants were found: two large rearrangements, two truncating and two missense mutations. The missense mutations were found to segregate in the families. Studies of allele frequencies, MSI and loss of immunostaning in tumours from family members further supports the hypothesis that these missense changes play a role in Lynch syndrome, as do the non-conservative nature and evolutionary conservation of the amino acid exchanges. Five families had mutations in MLH1, five in MSH2, and six in MSH6. The unexpectedly large impact of MSH6 was in genealogical studies shown to be due to a founder effect. Cumulative risk studies showed that the MSH6 families, despite their late age of onset, have a high lifetime risk for all Lynch syndrome-related cancers, significantly higher in women (89% by age 80 years) than in men (69%). The gender differences are in part due to high endometrial (70%) and ovarian cancer risk (33%) in addition to the high colorectal cancer risk (60%). These findings are of great importance for counselling and surveillance of families with MSH6 mutations. Finally, in a large family with MSI-negative hereditary colorectal cancer for which the MMR genes and APC had been excluded as possible causes, a genome-wide linkage analysis was performed, resulting in a suggested linkage to chromosome 7. Conclusions: Relatives of probands with MSI-positive, double primary colorectal and endometrial cancer diagnosed before the age of 50 years have significantly increased risks of Lynch syndrome-related cancers. MSH6 mutations, which have unusually high impact in this study population due to a founder effect, confer high cumulative risks of cancer despite the generally late age of onset.

2-Methoxyestradiol (2-ME), a metabolite of 17β-estradiol, is a potent antitumor and antiangiogenesis agent in vitro and in vivo. This study aimed to investigate the effects of 2-ME on human cervical and endometrial cancers in vitro and in vivo. Human cervical cancer HeLaS3 cells, endometrial cancer HEC-1-A and RL-95-2 cells, and severe combined immune deficient (SCID) mice were used. On cervical cancer HeLaS3 cells, 2-ME inhibited the cell growth which is accompanied by apoptosis via iNOS pathway and by G2/M cell cycle arrest. 2-ME had slight effects on normal cervical epithelial cells. In vivo on SCID mice, 2-ME (75 mg/kg p.o.) inhibited the growth of human cervical carcinoma by 34% (p &lt; 0.05) and showed slight side effects to liver and spleen. On human endometrial cancer cells (HEC-1-A and RL-95-2 cells), 2-ME inhibited the growth by blocking cell cycle progress in S- and G2/M-phase in both cell types, and by inducing apoptosis in HEC-1-A cells and by causing necrosis in RL-95-2 cells. 2-ME had no effects on normal endometrial cells. The apoptotic effect, in HEC-1-A cells, was prevented by iNOS-inhibitor 1400W and eliminated by Caspase-inhibitor Z-VAD-FMK. The necrosis, on RL-95-2 cells, was due to a severe disruption of the mitochondrial membrane potential. Unfortunately, 2-ME had no significant effects on endometrial cancer xenografts. It showed slight toxicity to liver, spleen and proliferative effect on uterus. In conclusion, 2-ME inhibits the growth of human cervical and endometrial cancer cells in vitro. However, a weaker anti-tumor effect was observed in our animal model and 2-ME was slightly toxic to liver and spleen. Considering the proliferative effect on uterus, 2-ME might not be a suitable therapeutic agent in gynecological tumors.

No description available.

Objectives: Preoperative ultrasound including assessment of local extent of disease in uterus, adnexal involvement and pelvic spread is recommended staging examination in patients with endometrial cancer. It is routinely based on subjective assessment by experienced sonographists. The main aim of the study was to assess if the objective methods based on simple measurements and calculations have diagnostic performance comparable to that of subjective evaluation in detection of deep myometrial invasion. Two traditional objective techniques were tested - (1) deepest invasion / normal myometrium width ratio proposed by Gordon and (2) tumor / uterine anteroposterior diameter ratio introduced by Karlsson. Methods: The prospective diagnostic accuracy study was initiated at Gynecologic Oncology Centre. All consecutive patients with histologically verified endometrial cancer undergoing transvaginal or transrectal sonography using predefined study protocol followed by surgical staging procedure were prospectively enrolled . Local staging of each endometrial tumor was subjectively evaluated by one of experienced sonographists, myometrial invasion was assessed as deep (≥ 50 %) or superficial (˂ 50 %) and cervical stromal involvement as present or absent. Concurrently, the depth of myometrial invasion was...

O câncer de endométrio tem incidência crescente, principalmente nos países desenvolvidos, devido ao estilo de vida moderno, aumento de casos de obesidade e diabetes, e diversos outros fatores que, em conjunto, estão tornando esta neoplasia na mais comum no trato reprodutor feminino. Ele é bastante influenciado pelo estado hormonal e por fatores reprodutivos das pacientes. Assim, é mais frequente no período pós-menopausa, quando pode ocorrer um desequilíbrio na sinalização do estrogênio. A diabetes e a obesidade são causadas, principalmente, pelo excesso de triglicerídeos e glicose circulantes, e pela resistência à insulina. A hiperglicemia leva à produção excessiva de insulina e do fator de crescimento semelhante à insulina tipo 1 (IGF1), sendo que estes hormônios são considerados antiapoptóticos e promotores da proliferação celular. Sabe-se que eles agem por vias semelhantes e que, provavelmente, o mecanismo responsável pela proliferação provocada por eles está associado à via PI3K/Akt/mTOR. Desta forma, avaliamos a expressão gênica de 92 genes na rota de sinalização do IGF1R em câncer de endométrio (n=3) e endométrio normal (n=2), através da técnica de qRT-PCR (ensaio TaqMan® Array Human IGF1R Signaling). Dentro destes genes, alguns estão envolvidos diretamente com a via PI3K/Akt/MAPK, outros estão implicados em processos como proliferação, diferenciação, tumorigênese, apoptose, resposta imune, síntese proteica, entre outros. Avaliamos, também, os níveis proteicos do receptor do fator de crescimento semelhante à insulina (IGF1R), IGF1 e receptor da insulina (IR) pela técnica de imunohistoquímica, além da funcionalidade geral dos 4 genes mais diferencialmente expressos no câncer de endométrio Observamos que, dos 92 genes, 26 foram expressos somente no grupo câncer - CACNA1H, CRK, EIF2B5, ELK1, FRAP1 (MTOR), GYS1, HRAS, IGF2, IKBKB, IKBKE, ITPR3, KRAS, NFAT5, NFATC1, NFKB1, NFKBIB, NFKBIE, PIK3CA, PIK3CB, PLCB1, PLCB2, PLCG2, PRKCZ, RELB, SHC1 e YWHAZ; 46 tiveram expressão aumentada no grupo câncer de endométrio - AKT1, AKT2, ARAF, ATF4, BAD, BRAF, CACNA1C, CALM1, CALM2, CALM3, CREB1, EIF4E, FOXO3, GSK3B, IGF1, IGF1R, IKBKG, IRS1, MAP2K1, MAP2K2, MAPK3, MEF2C, MEF2D, NFATC2, NFATC3. NFKB2, NFKBIA, NRAS, PDPK1, PIK3CD, PIK3R1, PIK3R2, PLCG1, PPP3CA, PPP3R1, PRKCI, RAF1, RAPGEF1, RELA, RPS6, RPS6KB1, SOS1, YWHAB, YWHAE, YWHAH e YWHAQ, um não apresentou expressão em nenhum dos grupos (SLC2A4) e não foi possível analisar os restantes 20 genes, pois não foram expressos em todas as amostras. Quanto à expressão das proteínas IGF1R, IGF1 e IR, todas se mostraram mais expressas no câncer de endométrio e que se encontram localizadas principalmente no citoplasma das células. Assim, este trabalho mostra que a sinalização do IGF1R pode ter participação importante na aquisição do fenótipo maligno das células endometriais, e que o aumento das moléculas efetoras desta via no câncer de endométrio provavelmente está relacionado ao seu papel mitogênico. / Endometrial cancer has a growing incidence, especially in developed countries, because of the modern lifestyle, increased cases of obesity and diabetes, and several other factors that together make this disease the most common in the female reproductive tract. Endometrial cancer is strongly influenced by the hormonal state and by the reproductive factors of the patients. Thus, it is attributed to the postmenopausal period, when estrogen signaling can be unbalanced, and consequently lead to malignant proliferative patterns. Diabetes and obesity are caused mainly by the excess of circulating triglycerides and glucose, and by insulin resistance. Hyperglycemia leads to excessive production of insulin and IGF1.These hormones are considered to have antiapoptotic effects and to promote cell proliferation. It is known that they are very similar pathways, and the mechanism responsible for this proliferation is associated with the PI3K/Akt/mTOR pathway. Thus, we evaluated the expression of 92 genes in IGF1R signaling pathway in endometrial cancer (n = 3) and normal endometrium (n = 2), using qRT-PCR (TaqMan® Array Human IGF1R Signaling test). Within these genes, some are in the PI3K/Akt/MAPK pathways, others are involved in proliferation, differentiation, tumorigenesis, apoptosis, immune response, protein synthesis, among others We also evaluated the protein levels of IGF1R, IGF1 and IR by immunohistochemistry, as well as the general functionality of the 4 most differentially expressed genes in endometrial cancer. We found that 26 genes were expressed only in endometrial cancer - CACNA1H, CRK, EIF2B5, ELK1, FRAP1 (mTOR), GYS1, HRAS, IGF2, IKBKB, IKBKE, ITPR3, KRAS, NFAT5, NFATc1, NFKB1, NFKBIB, NFKBIE, PIK3CA, PIK3CB, PLCB1, PLCB2, PLCG2, PRKCZ, RELB, SHC1 and YWHAZ; 46 had increased expression in endometrial cancer, when compared to control group - AKT1, AKT2, ARAF, ATF4, BAD, BRAF, CACNA1C, CALM1, CALM2, CALM3, CREB1, eIF4E, FOXO3, GSK3B, IGF1, IGF1R IKBKG, IRS1, MAP2K1, MAP2K2, MAPK3 , MEF2C, MEF2D, NFATC2, NFATC3. NFKB2, NFKBIA, PIK3R1, PIK3R2, PLCG1, PPP3CA, PPP3R1, PRKCI, RAF1, RAPGEF1, RELA, RPS6, RPS6KB1, SOS1, YWHAB, YWHAE, YWHAH and YWHAQ, one showed no expression in neither groups (SLC2A4) and the other 20 were not expressed in all samples, so we decided not to analyze them. As for the expression of IGF1R, IGF1 and IR proteins, all them showed increased expression in endometrial cancer and were localized in the citoplasm. Thus, this work shows that IGF1R signaling may play an important role in the acquisition of a malignant phenotype by endometrial cells, and that the increase of these effectors in endometrial cancer is related to its mitogenic effects.

O câncer de endométrio tem incidência crescente, principalmente nos países desenvolvidos, devido ao estilo de vida moderno, aumento de casos de obesidade e diabetes, e diversos outros fatores que, em conjunto, estão tornando esta neoplasia na mais comum no trato reprodutor feminino. Ele é bastante influenciado pelo estado hormonal e por fatores reprodutivos das pacientes. Assim, é mais frequente no período pós-menopausa, quando pode ocorrer um desequilíbrio na sinalização do estrogênio. A diabetes e a obesidade são causadas, principalmente, pelo excesso de triglicerídeos e glicose circulantes, e pela resistência à insulina. A hiperglicemia leva à produção excessiva de insulina e do fator de crescimento semelhante à insulina tipo 1 (IGF1), sendo que estes hormônios são considerados antiapoptóticos e promotores da proliferação celular. Sabe-se que eles agem por vias semelhantes e que, provavelmente, o mecanismo responsável pela proliferação provocada por eles está associado à via PI3K/Akt/mTOR. Desta forma, avaliamos a expressão gênica de 92 genes na rota de sinalização do IGF1R em câncer de endométrio (n=3) e endométrio normal (n=2), através da técnica de qRT-PCR (ensaio TaqMan® Array Human IGF1R Signaling). Dentro destes genes, alguns estão envolvidos diretamente com a via PI3K/Akt/MAPK, outros estão implicados em processos como proliferação, diferenciação, tumorigênese, apoptose, resposta imune, síntese proteica, entre outros. Avaliamos, também, os níveis proteicos do receptor do fator de crescimento semelhante à insulina (IGF1R), IGF1 e receptor da insulina (IR) pela técnica de imunohistoquímica, além da funcionalidade geral dos 4 genes mais diferencialmente expressos no câncer de endométrio Observamos que, dos 92 genes, 26 foram expressos somente no grupo câncer - CACNA1H, CRK, EIF2B5, ELK1, FRAP1 (MTOR), GYS1, HRAS, IGF2, IKBKB, IKBKE, ITPR3, KRAS, NFAT5, NFATC1, NFKB1, NFKBIB, NFKBIE, PIK3CA, PIK3CB, PLCB1, PLCB2, PLCG2, PRKCZ, RELB, SHC1 e YWHAZ; 46 tiveram expressão aumentada no grupo câncer de endométrio - AKT1, AKT2, ARAF, ATF4, BAD, BRAF, CACNA1C, CALM1, CALM2, CALM3, CREB1, EIF4E, FOXO3, GSK3B, IGF1, IGF1R, IKBKG, IRS1, MAP2K1, MAP2K2, MAPK3, MEF2C, MEF2D, NFATC2, NFATC3. NFKB2, NFKBIA, NRAS, PDPK1, PIK3CD, PIK3R1, PIK3R2, PLCG1, PPP3CA, PPP3R1, PRKCI, RAF1, RAPGEF1, RELA, RPS6, RPS6KB1, SOS1, YWHAB, YWHAE, YWHAH e YWHAQ, um não apresentou expressão em nenhum dos grupos (SLC2A4) e não foi possível analisar os restantes 20 genes, pois não foram expressos em todas as amostras. Quanto à expressão das proteínas IGF1R, IGF1 e IR, todas se mostraram mais expressas no câncer de endométrio e que se encontram localizadas principalmente no citoplasma das células. Assim, este trabalho mostra que a sinalização do IGF1R pode ter participação importante na aquisição do fenótipo maligno das células endometriais, e que o aumento das moléculas efetoras desta via no câncer de endométrio provavelmente está relacionado ao seu papel mitogênico. / Endometrial cancer has a growing incidence, especially in developed countries, because of the modern lifestyle, increased cases of obesity and diabetes, and several other factors that together make this disease the most common in the female reproductive tract. Endometrial cancer is strongly influenced by the hormonal state and by the reproductive factors of the patients. Thus, it is attributed to the postmenopausal period, when estrogen signaling can be unbalanced, and consequently lead to malignant proliferative patterns. Diabetes and obesity are caused mainly by the excess of circulating triglycerides and glucose, and by insulin resistance. Hyperglycemia leads to excessive production of insulin and IGF1.These hormones are considered to have antiapoptotic effects and to promote cell proliferation. It is known that they are very similar pathways, and the mechanism responsible for this proliferation is associated with the PI3K/Akt/mTOR pathway. Thus, we evaluated the expression of 92 genes in IGF1R signaling pathway in endometrial cancer (n = 3) and normal endometrium (n = 2), using qRT-PCR (TaqMan® Array Human IGF1R Signaling test). Within these genes, some are in the PI3K/Akt/MAPK pathways, others are involved in proliferation, differentiation, tumorigenesis, apoptosis, immune response, protein synthesis, among others We also evaluated the protein levels of IGF1R, IGF1 and IR by immunohistochemistry, as well as the general functionality of the 4 most differentially expressed genes in endometrial cancer. We found that 26 genes were expressed only in endometrial cancer - CACNA1H, CRK, EIF2B5, ELK1, FRAP1 (mTOR), GYS1, HRAS, IGF2, IKBKB, IKBKE, ITPR3, KRAS, NFAT5, NFATc1, NFKB1, NFKBIB, NFKBIE, PIK3CA, PIK3CB, PLCB1, PLCB2, PLCG2, PRKCZ, RELB, SHC1 and YWHAZ; 46 had increased expression in endometrial cancer, when compared to control group - AKT1, AKT2, ARAF, ATF4, BAD, BRAF, CACNA1C, CALM1, CALM2, CALM3, CREB1, eIF4E, FOXO3, GSK3B, IGF1, IGF1R IKBKG, IRS1, MAP2K1, MAP2K2, MAPK3 , MEF2C, MEF2D, NFATC2, NFATC3. NFKB2, NFKBIA, PIK3R1, PIK3R2, PLCG1, PPP3CA, PPP3R1, PRKCI, RAF1, RAPGEF1, RELA, RPS6, RPS6KB1, SOS1, YWHAB, YWHAE, YWHAH and YWHAQ, one showed no expression in neither groups (SLC2A4) and the other 20 were not expressed in all samples, so we decided not to analyze them. As for the expression of IGF1R, IGF1 and IR proteins, all them showed increased expression in endometrial cancer and were localized in the citoplasm. Thus, this work shows that IGF1R signaling may play an important role in the acquisition of a malignant phenotype by endometrial cells, and that the increase of these effectors in endometrial cancer is related to its mitogenic effects.

Contexte : Le cancer de l'endomètre est le plus fréquent des cancers gynécologiques. Il a été suggéré que les traitements oncologiques entraînent des dysfonctions des muscles du plancher pelvien. Ces dysfonctions pourraient contribuer au développement de conditions débilitantes comme la douleur lors des relations sexuelles (dyspareunie) qui atteint plus de la moitié des survivantes. Or, à l'heure actuelle, aucune étude n'a investigué la fonction des muscles du plancher pelvien en lien avec la dyspareunie chez des survivantes d'un cancer de l'endomètre. Objectifs : L'objectif principal vise à explorer les différences quant à la fonction des muscles du plancher pelvien entre des survivantes d'un cancer de l'endomètre atteintes de dyspareunie et des femmes sans douleur ayant subi l'hystérectomie totale pour des raisons bénignes. L'objectif secondaire est d'explorer les différences entre les deux groupes quant aux variables urogynécologiques, sexuelles, psychologiques et sociales. Méthodologie : Dans cette étude comparative exploratoire bicentrique, des survivantes d'un cancer de l'endomètre atteintes de dyspareunie (n=7) et des femmes asymptomatiques (n=7) ont assisté à une séance d'évaluation menée par une physiothérapeute. Les deux groupes ont été équilibrés selon l'âge, l'indice de masse corporelle et le nombre d'accouchements par voie vaginale. La fonction des muscles du plancher pelvien, y compris le tonus, la force maximale, la vitesse de contraction, la coordination et l'endurance, a été évaluée à l'aide du spéculum dynamométrique. Des questionnaires validés ont permis d'évaluer les variables secondaires. Des tests de Mann-Whitney ont été employés pour comparer les deux groupes quant à la fonction des muscles du plancher pelvien et les variables urogynécologiques, sexuelles, psychologiques et sociales (!=0,050). Résultats : Concernant la fonction des muscles du plancher pelvien, les survivantes atteintes de dyspareunie ont démontré un tonus à une ouverture vaginale minimale supérieur (p=0,018) et une endurance inférieure (p=0,048) aux femmes asymptomatiques. Les survivantes ont également présenté plus d'incontinence fécale (p=0,005) et une fonction sexuelle inférieure (p=0,004) comparativement aux femmes asymptomatiques. Aucune différence n'a été détectée pour les variables psychologiques et sociales. Conclusion : Les résultats de cette étude exploratoire suggèrent des dysfonctions des muscles du plancher pelvien, notamment un tonus supérieur et une endurance inférieure, chez les survivantes d'un cancer de l'endomètre atteintes de dyspareunie. D'autres études sont nécessaires afin de confirmer ces résultats. Ces constats préliminaires pourraient servir d'assises pour mieux comprendre les dysfonctions des muscles du plancher pelvien impliquées dans la dyspareunie chez cette population. / Abstract : Context: Endometrial cancer is the most common cancer in gynecological cancers. Oncological treatments are suggested to cause pelvic floor muscle dysfunction that could contribute to the development of debilitating conditions such as pain during sexual intercourse (dyspareunia), which affects more than half of survivors. However, to date, no study investigated pelvic floor muscle function in relation to dyspareunia in endometrial cancer survivors. Objectives: The main objective is to explore differences in pelvic floor muscle function between endometrial cancer survivors with dyspareunia and women without pain who underwent a total hysterectomy for benign conditions. The secondary objective is to explore differences between the two groups on urogynecological, sexual, psychological and social variables. Methodology: In this exploratory, bicentric comparative study, endometrial cancer survivors with dyspareunia (n=7) and asymptomatic women (n=7) attended one evaluation session conducted by a physiotherapist. The two groups were balanced in terms of age, body mass index and number of vaginal deliveries. The pelvic floor muscle function, including tone, maximal strength, contraction speed, coordination and endurance, was assessed with the dynamometric speculum. Validated questionnaires were used to evaluate secondary variables. Mann-Whitney tests were used to compare the two groups on muscular, urogynecological, sexual, psychological and social variables (!=0.050). Results: Concerning pelvic floor muscle function, survivors with dyspareunia demonstrated higher tone at a minimal vaginal aperture (p=0.018) and lower endurance (p=0.048) compared to asymptomatic women. Survivors also presented more fecal incontinence (p=0.005) and lower sexual function (p=0.004) compared to asymptomatic women. No differences were detected for psychological and social variables. Conclusion: The results of this exploratory study suggest impaired pelvic floor muscle function, notably higher tone and lower endurance, in endometrial cancer survivors with dyspareunia. Further studies are needed to confirm these findings. This preliminary evidence can be used as empirical data to better understand pelvic floor muscle impairments implicated in dyspareunia in this population.